Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 1.898
Filtrer
2.
Cell Rep ; 43(6): 114243, 2024 Jun 25.
Article de Anglais | MEDLINE | ID: mdl-38805398

RÉSUMÉ

Xeroderma pigmentosum (XP) is caused by defective nucleotide excision repair of DNA damage. This results in hypersensitivity to ultraviolet light and increased skin cancer risk, as sunlight-induced photoproducts remain unrepaired. However, many XP patients also display early-onset neurodegeneration, which leads to premature death. The mechanism of neurodegeneration is unknown. Here, we investigate XP neurodegeneration using pluripotent stem cells derived from XP patients and healthy relatives, performing functional multi-omics on samples during neuronal differentiation. We show substantially increased levels of 5',8-cyclopurine and 8-oxopurine in XP neuronal DNA secondary to marked oxidative stress. Furthermore, we find that the endoplasmic reticulum stress response is upregulated and reversal of the mutant genotype is associated with phenotypic rescue. Critically, XP neurons exhibit inappropriate downregulation of the protein clearance ubiquitin-proteasome system (UPS). Chemical enhancement of UPS activity in XP neuronal models improves phenotypes, albeit inadequately. Although more work is required, this study presents insights with intervention potential.


Sujet(s)
Cellules souches pluripotentes induites , Xeroderma pigmentosum , Xeroderma pigmentosum/anatomopathologie , Xeroderma pigmentosum/métabolisme , Xeroderma pigmentosum/génétique , Cellules souches pluripotentes induites/métabolisme , Humains , Neurones/métabolisme , Neurones/anatomopathologie , Stress oxydatif , Stress du réticulum endoplasmique , Proteasome endopeptidase complex/métabolisme , Différenciation cellulaire , Altération de l'ADN , Modèles biologiques , Multi-omique
3.
Exp Eye Res ; 243: 109901, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38641197

RÉSUMÉ

Xeroderma pigmentosum (XP) is a rare genetic disorder characterized by injury to the ocular surface due to exposure to ultraviolet (UV) radiation. UV-induced damage in the cells leads to the formation of cyclobutane pyrimidine dimers (CPDs) and 6-4 pyrimidine-pyrimidone photoproducts that are repaired by the NER (Nucleotide Excision Repair) pathway. Mutations in the genes coding for NER proteins, as reported in XP patients, would lead to sub-optimal damage repair resulting in clinical signs varying from photo-keratitis to cancerous lesions on the ocular surface. Here, we aimed to provide evidence for the accumulation of DNA damage and activation of DNA repair pathway proteins in the corneal cells of patients with XP. Corneal buttons of patients who underwent penetrating keratoplasty were stained to quantify DNA damage and the presence of activated DNA damage response proteins (DDR) using specific antibodies. Positive staining for pH2A.X and thymidine dimers confirmed the presence of DNA damage in the corneal cells. Positive cells were found in both control corneas and XP samples however, unlike normal tissues, positive cells were found in all cell layers of XP samples indicating that these cells were sensitive to very low levels of UV. pH2A.X-positive cells were significantly more in XP corneas (p < 0.05) indicating the presence of double strand breaks in these tissues. A positive expression of phosphorylated-forms of DDR proteins was noted in XP corneas (unlike controls) such as ataxia telangiectasia mutated/Rad-3 related proteins (ATM/ATR), breast cancer-1 and checkpoint kinases-1 and -2. Nuclear localization of XPA was noted in XP samples which co-localized (calculated using Pearson's correlation) with pATM (0.9 ± 0.007) and pATR (0.6 ± 0.053). The increased presence of these in the nucleus confirms that unresolved DNA damage was accumulating in these cells thereby leading to prolonged activation of the damage response proteins. An increase in pp53 and TUNEL positive cells in the XP corneas indicated cell death likely driven by the p53 pathway. For comparison, cultured normal corneal epithelial cells were exposed to UV-radiation and stained for DDR proteins at 3, 6 and 24 h after irradiation to quantify the time taken by cells with intact DDR pathway to repair damage. These cells, when exposed to UV showed nuclear translocation of DDR proteins at 3 and 6 h which reduced significantly by 24 h confirming that the damaged DNA was being actively repaired leading to cell survival. The persistent presence of the DDR proteins in XP corneas indicates that damage is being actively recognized and DNA replication is stalled, thereby causing accumulation of damaged DNA leading to cell death, which would explain the cancer incidence and cell loss reported in these patients.


Sujet(s)
Altération de l'ADN , Réparation de l'ADN , Dimères de pyrimidine , Rayons ultraviolets , Xeroderma pigmentosum , Humains , Rayons ultraviolets/effets indésirables , Xeroderma pigmentosum/métabolisme , Xeroderma pigmentosum/génétique , Xeroderma pigmentosum/anatomopathologie , Dimères de pyrimidine/métabolisme , Kératoplastie transfixiante , Cornée/métabolisme , Cornée/anatomopathologie , Cornée/effets des radiations , Femelle , Adulte , Histone/métabolisme , Mâle , Adulte d'âge moyen , Protéines mutées dans l'ataxie-télangiectasie/métabolisme , Protéines mutées dans l'ataxie-télangiectasie/génétique , Adolescent , Jeune adulte
6.
Nat Commun ; 15(1): 2518, 2024 Mar 21.
Article de Anglais | MEDLINE | ID: mdl-38514641

RÉSUMÉ

DNA repair deficiency can lead to segmental phenotypes in humans and mice, in which certain tissues lose homeostasis while others remain seemingly unaffected. This may be due to different tissues facing varying levels of damage or having different reliance on specific DNA repair pathways. However, we find that the cellular response to DNA damage determines different tissue-specific outcomes. Here, we use a mouse model of the human XPF-ERCC1 progeroid syndrome (XFE) caused by loss of DNA repair. We find that p53, a central regulator of the cellular response to DNA damage, regulates tissue dysfunction in Ercc1-/- mice in different ways. We show that ablation of p53 rescues the loss of hematopoietic stem cells, and has no effect on kidney, germ cell or brain dysfunction, but exacerbates liver pathology and polyploidisation. Mechanistically, we find that p53 ablation led to the loss of cell-cycle regulation in the liver, with reduced p21 expression. Eventually, p16/Cdkn2a expression is induced, serving as a fail-safe brake to proliferation in the absence of the p53-p21 axis. Taken together, our data show that distinct and tissue-specific functions of p53, in response to DNA damage, play a crucial role in regulating tissue-specific phenotypes.


Sujet(s)
Protéine p53 suppresseur de tumeur , Xeroderma pigmentosum , Animaux , Humains , Souris , Altération de l'ADN , Réparation de l'ADN , Protéines de liaison à l'ADN/métabolisme , Protéine p53 suppresseur de tumeur/métabolisme , Xeroderma pigmentosum/génétique
7.
DNA Repair (Amst) ; 136: 103633, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38422792

RÉSUMÉ

Inherited photosensitivity syndromes are a heterogeneous group of genetic skin disorders with tremendous phenotypic variability, characterized by photosensitivity and defective DNA repair, especially nucleotide excision repair. A cohort of 17 Iranian families with heritable photosensitivity syndromes was evaluated to identify their genetic defect. The patients' DNA was analyzed with either whole-exome sequencing or RNA sequencing (RNA-Seq). The interpretations of the genomic results were guided by genome-wide homozygosity mapping. Haplotype analysis was performed for cases with recurrent mutations. RNA-Seq, in addition to mutation detection, was also utilized to confirm the pathogenicity. Thirteen sequence variants, including six previously unreported pathogenic variants, were disclosed in 17 Iranian families, with XPC as the most common mutated gene in 10 families (59%). In one patient, RNA-Seq, as a first-tier diagnostic approach, revealed a non-canonical homozygous germline variant: XPC:c.413-9 T > A. The Sashimi plot showed skipping of exon 4 with dramatic XPC down-expression. Haplotype analysis of XPC:c.2251-1 G>C and XPC:1243 C>T in four families showed common haplotypes of 1.7 Mb and 2.6 Mb, respectively, denoting a founder effect. Lastly, two extremely rare cases were presented in this report: a homozygous UVSSA:c .1990 C>T was disclosed, and ERCC2-related cerebro-oculo-facio-skeletal (COFS) syndrome with an early childhood death. A direct comparison of our data with the results of previously reported cohorts demonstrates the international mutation landscape of DNA repair-related photosensitivity disorders, although population-specific differences were observed.


Sujet(s)
Photodermatoses , Xeroderma pigmentosum , Humains , Enfant d'âge préscolaire , Consanguinité , Xeroderma pigmentosum/génétique , Famille élargie , Iran , Protéines de liaison à l'ADN/génétique , Mutation , Réparation de l'ADN , Photodermatoses/génétique , Protéine du groupe de complémentation D de Xeroderma pigmentosum , Protéines de transport
8.
BMJ Open ; 14(2): e077741, 2024 Feb 12.
Article de Anglais | MEDLINE | ID: mdl-38346891

RÉSUMÉ

OBJECTIVES: To determine the community's perception on the magnitude of Xeroderma pigmentosum (XP) disease and healthcare-seeking practices in Micheweni, Pemba in response to the public widespread information on the increased burden of the disease. DESIGN: Mixed-methods cross-sectional study. SETTING: Micheweni district, Pemba. PARTICIPANTS: 211 male and female adults in the household survey, three caretakers/parents of patients with XP in the case study, 20 key community leaders/influential people and health workers in in-depth interviews and 50 community members and other leaders in six focus groups. RESULTS: This study has revealed that XP disease exists in few families of which some of them have more than one child affected. The record review showed that there were a total of 17 patients who were diagnosed with the disease for the past 3 years, however only 10 were alive during the time of the survey. Findings from the community members revealed that several patients were believed to have XP disease and perceived causes include inheritance, food types, beliefs and other sociocultural practices. Stigma and discrimination were reported by caretakers and religious leaders. However, some cases believed to be XP were identified as other skin conditions when clinical examination was performed by the team of our researchers. There is a great confusion about XP and other skin diseases. CONCLUSION: The study has shown that XP affects only few families, hence termed as concentrated rather than a generalised disease. Due to the rareness of the disease, majority of people in the district are unaware of the disease, hence confusing it with other skin conditions. There is a need for the government in collaboration with other stakeholders to provide educational programme to community members about the disease to address the misconception about the magnitude of the disease.


Sujet(s)
Dermatite , Xeroderma pigmentosum , Adulte , Enfant , Humains , Mâle , Femelle , Xeroderma pigmentosum/génétique , Études transversales , Îles de l'Océan Indien
9.
BMC Oral Health ; 24(1): 163, 2024 Feb 01.
Article de Anglais | MEDLINE | ID: mdl-38302989

RÉSUMÉ

BACKGROUND: Xeroderma pigmentosum (XP) is an extremely rare and severe form of photosensitivity. It is classified into types A-G or V according to the gene responsible for the disease. The progression and severity of symptoms vary depending on the type. Although dysphagia caused by decreased swallowing function and dental malposition due to stenosis of the dentition in the facial and oral regions is common, it has not been reported in detail. We report three cases of type A XP, in which central and peripheral neurological symptoms appeared early on and progressed rapidly. We describe the oral function of these patients, focusing on the swallowing function and dentition malposition. CASE PRESENTATION: Two males (27 and 25 years old) and one female (28 years old) presented with diverse neurological symptoms. We focused on the relationship between the changes in swallowing and oral functions and conditions due to decline in physical function. Some effects were observed by addressing the decline in swallowing and oral functions. In particular, a dental approach to manage the narrowing of the dentition, which was observed in all three patients, improved the swallowing and oral functions and maintained the current status of these functions. CONCLUSIONS: In type A XP, early decline in oral and swallowing functions is caused by the early decline in physical function, and it is necessary to monitor the condition at an early stage.


Sujet(s)
Troubles de la déglutition , Xeroderma pigmentosum , Mâle , Humains , Femelle , Adulte , Xeroderma pigmentosum/complications , Xeroderma pigmentosum/diagnostic , Xeroderma pigmentosum/génétique , Déglutition , Troubles de la déglutition/étiologie
10.
Sci Rep ; 14(1): 1117, 2024 01 11.
Article de Anglais | MEDLINE | ID: mdl-38212351

RÉSUMÉ

DNA polymerase eta (Polη) is the only translesion synthesis polymerase capable of error-free bypass of UV-induced cyclobutane pyrimidine dimers. A deficiency in Polη function is associated with the human disease Xeroderma pigmentosum variant (XPV). We hereby report the case of a 60-year-old woman known for XPV and carrying a Polη Thr191Pro variant in homozygosity. We further characterize the variant in vitro and in vivo, providing molecular evidence that the substitution abrogates polymerase activity and results in UV sensitivity through deficient damage bypass. This is the first functional molecular characterization of a missense variant of Polη, whose reported pathogenic variants have thus far been loss of function truncation or frameshift mutations. Our work allows the upgrading of Polη Thr191Pro from 'variant of uncertain significance' to 'likely pathogenic mutant', bearing direct impact on molecular diagnosis and genetic counseling. Furthermore, we have established a robust experimental approach that will allow a precise molecular analysis of further missense mutations possibly linked to XPV. Finally, it provides insight into critical Polη residues that may be targeted to develop small molecule inhibitors for cancer therapeutics.


Sujet(s)
Xeroderma pigmentosum , Humains , Adulte d'âge moyen , Altération de l'ADN , Mutation faux-sens , Proline/génétique , Dimères de pyrimidine , Rayons ultraviolets , Xeroderma pigmentosum/génétique , Xeroderma pigmentosum/anatomopathologie , Femelle
11.
Environ Mol Mutagen ; 65 Suppl 1: 72-81, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-37545038

RÉSUMÉ

DNA damage occurs throughout life from a variety of sources, and it is imperative to repair damage in a timely manner to maintain genome stability. Thus, DNA repair mechanisms are a fundamental part of life. Nucleotide excision repair (NER) plays an important role in the removal of bulky DNA adducts, such as cyclobutane pyrimidine dimers from ultraviolet light or DNA crosslinking damage from platinum-based chemotherapeutics, such as cisplatin. A main component for the NER pathway is transcription factor IIH (TFIIH), a multifunctional, 10-subunit protein complex with crucial roles in both transcription and NER. In transcription, TFIIH is a component of the pre-initiation complex and is important for promoter opening and the phosphorylation of RNA Polymerase II (RNA Pol II). During repair, TFIIH is important for DNA unwinding, recruitment of downstream repair factors, and verification of the bulky lesion. Several different disease states can arise from mutations within subunits of the TFIIH complex. Most strikingly are xeroderma pigmentosum (XP), XP combined with Cockayne syndrome (CS), and trichothiodystrophy (TTD). Here, we summarize the recruitment and functions of TFIIH in the two NER subpathways, global genomic (GG-NER) and transcription-coupled NER (TC-NER). We will also discuss how TFIIH's roles in the two subpathways lead to different genetic disorders.


Sujet(s)
Réparation par excision , Xeroderma pigmentosum , Humains , Réparation de l'ADN/génétique , Xeroderma pigmentosum/génétique , Facteur de transcription TFIIH/génétique , Facteur de transcription TFIIH/métabolisme , Altération de l'ADN/génétique , ADN/génétique , Nucléotides , Transcription génétique
12.
Photochem Photobiol ; 100(1): 4-18, 2024.
Article de Anglais | MEDLINE | ID: mdl-37926965

RÉSUMÉ

Xeroderma pigmentosum (XP) variant cells are deficient in the translesion synthesis (TLS) DNA polymerase Polη (eta). This protein contributes to DNA damage tolerance, bypassing unrepaired UV photoproducts and allowing S-phase progression with minimal delay. In the absence of Polη, backup polymerases perform TLS of UV lesions. However, which polymerase plays this role in human cells remains an open question. Here, we investigated the potential role of Polι (iota) in bypassing ultraviolet (UV) induced photoproducts in the absence of Polη, using NER-deficient (XP-C) cells knocked down for Polι and/or Polη genes. Our results indicate that cells lacking either Polι or Polη have increased sensitivity to UVC radiation. The lack of both TLS polymerases led to increased cell death and defects in proliferation and migration. Loss of both polymerases induces a significant replication fork arrest and G1/S-phase blockage, compared to the lack of Polη alone. In conclusion, we propose that Polι acts as a bona fide backup for Polη in the TLS of UV-photoproducts.


Sujet(s)
, Xeroderma pigmentosum , Humains , Altération de l'ADN , , Réplication de l'ADN , Xeroderma pigmentosum/génétique , Rayons ultraviolets , Réparation de l'ADN
13.
Int J Dermatol ; 63(1): 59-72, 2024 Jan.
Article de Anglais | MEDLINE | ID: mdl-37964400

RÉSUMÉ

BACKGROUND: Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder presenting with an inability to repair UV-induced DNA damage. This can lead to the development of neoplasms affecting multiple organ systems, with onset often in childhood. Unfortunately, no cure currently exists for XP, and management strategies focus on sun protection and early intervention for malignancies. Although most skin problems in XP patients are UV induced, various oral lesions are also described. However, the literature has not extensively characterized the oral manifestations and their prognostic significance. METHODS: We conducted a comprehensive review to evaluate the prevalence and nature of oral mucosal lesions in pediatric XP patients. RESULTS: Our literature search yielded 130 pediatric XP patients with oral involvement and 210 associated tumoral or non-tumoral lesions. Squamous cell carcinoma was the most common type of oral mucosal tumor reported, with other malignancies including basal cell carcinoma, melanoma, angiosarcoma, fibrosarcoma, and trichilemmal carcinoma. CONCLUSION: Given the potential morbidity and mortality associated with oral mucosal tumors in XP patients, our study aims to raise awareness of these manifestations. Early diagnosis and treatment are crucial for managing these lesions effectively, and routine oral exams should be considered a critical component of dermatological evaluations for XP patients, especially in the pediatric age group.


Sujet(s)
Carcinome basocellulaire , Mélanome , Tumeurs de la bouche , Tumeurs cutanées , Xeroderma pigmentosum , Humains , Enfant , Xeroderma pigmentosum/complications , Xeroderma pigmentosum/diagnostic , Xeroderma pigmentosum/génétique , Tumeurs cutanées/diagnostic , Tumeurs cutanées/épidémiologie , Tumeurs cutanées/étiologie , Muqueuse de la bouche/anatomopathologie , Carcinome basocellulaire/anatomopathologie , Mélanome/complications , Tumeurs de la bouche/étiologie , Tumeurs de la bouche/thérapie , Réparation de l'ADN
14.
Brain ; 146(12): 5044-5059, 2023 12 01.
Article de Anglais | MEDLINE | ID: mdl-38040034

RÉSUMÉ

Xeroderma pigmentosum (XP) results from biallelic mutations in any of eight genes involved in DNA repair systems, thus defining eight different genotypes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XP variant or XPV). In addition to cutaneous and ophthalmological features, some patients present with XP neurological disease. It is unknown whether the different neurological signs and their progression differ among groups. Therefore, we aim to characterize the XP neurological disease and its evolution in the heterogeneous UK XP cohort. Patients with XP were followed in the UK National XP Service, from 2009 to 2021. Age of onset for different events was recorded. Cerebellar ataxia and additional neurological signs and symptoms were rated with the Scale for the Assessment and Rating of Ataxia (SARA), the Inventory of Non-Ataxia Signs (INAS) and the Activities of Daily Living questionnaire (ADL). Patients' mutations received scores based on their predicted effects. Data from available ancillary tests were collected. Ninety-three XP patients were recruited. Thirty-six (38.7%) reported neurological symptoms, especially in the XPA, XPD and XPG groups, with early-onset and late-onset forms, and typically appearing after cutaneous and ophthalmological symptoms. XPA, XPD and XPG patients showed higher SARA scores compared to XPC, XPE and XPV. SARA total scores significantly increased over time in XPD (0.91 points/year, 95% confidence interval: 0.61, 1.21) and XPA (0.63 points/year, 95% confidence interval: 0.38, 0.89). Hyporeflexia, hypopallesthaesia, upper motor neuron signs, chorea, dystonia, oculomotor signs and cognitive impairment were frequent findings in XPA, XPD and XPG. Cerebellar and global brain atrophy, axonal sensory and sensorimotor neuropathies, and sensorineural hearing loss were common findings in patients. Some XPC, XPE and XPV cases presented with abnormalities on examination and/or ancillary tests, suggesting underlying neurological involvement. More severe mutations were associated with a faster progression in SARA total score in XPA (0.40 points/year per 1-unit increase in severity score) and XPD (0.60 points/year per 1-unit increase), and in ADL total score in XPA (0.35 points/year per 1-unit increase). Symptomatic and asymptomatic forms of neurological disease are frequent in XP patients, and neurological symptoms can be an important cause of disability. Typically, the neurological disease will be preceded by cutaneous and ophthalmological features, and these should be actively searched in patients with idiopathic late-onset neurological syndromes. Scales assessing cerebellar function, especially walking and speech, and disability can show progression in some of the groups. Mutation severity can be used as a prognostic biomarker for stratification purposes in clinical trials.


Sujet(s)
Maladies du système nerveux central , Xeroderma pigmentosum , Humains , Xeroderma pigmentosum/complications , Xeroderma pigmentosum/génétique , Xeroderma pigmentosum/diagnostic , Activités de la vie quotidienne , Études prospectives , Réparation de l'ADN , Mutation/génétique
15.
DNA Repair (Amst) ; 132: 103568, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-37977600

RÉSUMÉ

The heterodecameric transcription factor IIH (TFIIH) functions in multiple cellular processes, foremost in nucleotide excision repair (NER) and transcription initiation by RNA polymerase II. TFIIH is essential for life and hereditary mutations in TFIIH cause the devastating human syndromes xeroderma pigmentosum, Cockayne syndrome or trichothiodystrophy, or combinations of these. In NER, TFIIH binds to DNA after DNA damage is detected and, using its translocase and helicase subunits XPB and XPD, opens up the DNA and checks for the presence of DNA damage. This central activity leads to dual incision and removal of the DNA strand containing the damage, after which the resulting DNA gap is restored. In this review, we discuss new structural and mechanistic insights into the central function of TFIIH in NER. Moreover, we provide an elaborate overview of all currently known patients and diseases associated with inherited TFIIH mutations and describe how our understanding of TFIIH function in NER and transcription can explain the different disease features caused by TFIIH deficiency.


Sujet(s)
Protéine du groupe de complémentation D de Xeroderma pigmentosum , Xeroderma pigmentosum , Humains , Facteur de transcription TFIIH/génétique , Facteur de transcription TFIIH/métabolisme , Protéine du groupe de complémentation D de Xeroderma pigmentosum/génétique , Protéine du groupe de complémentation D de Xeroderma pigmentosum/métabolisme , Réparation de l'ADN , Xeroderma pigmentosum/génétique , ADN/génétique
16.
Genes (Basel) ; 14(11)2023 Nov 15.
Article de Anglais | MEDLINE | ID: mdl-38003022

RÉSUMÉ

Advances in genetic technologies have made genetic testing more accessible than ever before. However, depending on national, regional, legal, and health insurance circumstances, testing procedures may still need to be streamlined in real-world clinical practice. In cases of autosomal recessive disease with consanguinity, the mutation locus is necessarily isodisomy because both alleles originate from a common ancestral chromosome. Based on this premise, we implemented integrated genetic diagnostic methods using SNP array screening and long range PCR-based targeted NGS in a Japanese patient with xeroderma pigmentosum (XP) under the limitation of the national health insurance system. SNP array results showed isodisomy only in XPC and ERCC4 loci. NGS, with a minimal set of long-range PCR primers, detected a homozygous frameshift mutation in XPC; NM_004628.5:c.218_219insT p.(Lys73AsnfsTer9), confirmed by Sanger sequencing, leading to a rapid diagnosis of XP group C. This shortcut strategy is applicable to all autosomal recessive diseases caused by consanguineous marriages, especially in scenarios with a moderate number of genes to test, a common occurrence in clinical genetic practice.


Sujet(s)
Xeroderma pigmentosum , Humains , Xeroderma pigmentosum/diagnostic , Xeroderma pigmentosum/génétique , Xeroderma pigmentosum/épidémiologie , Consanguinité , Séquençage nucléotidique à haut débit , Réaction de polymérisation en chaîne
17.
Mol Cell ; 83(20): 3669-3678.e7, 2023 10 19.
Article de Anglais | MEDLINE | ID: mdl-37816354

RÉSUMÉ

UV irradiation induces "bulky" DNA photodimers such as (6-4)-photoproducts and cyclobutane pyrimidine dimers that are removed by nucleotide excision repair, a complex process defective in the sunlight-sensitive and cancer-prone disease xeroderma pigmentosum. Some bacteria and lower eukaryotes can also repair photodimers by enzymatically simpler mechanisms, but such pathways have not been reported in normal human cells. Here, we have identified such a mechanism. We show that normal human cells can employ a DNA base excision repair process involving NTH1, APE1, PARP1, XRCC1, and FEN1 to rapidly remove a subset of photodimers at early times following UVC irradiation. Loss of these proteins slows the early rate of repair of photodimers in normal cells, ablates their residual repair in xeroderma pigmentosum cells, and increases UVC sensitivity ∼2-fold. These data reveal that human cells can excise photodimers using a long-patch base excision repair process that functions additively but independently of nucleotide excision repair.


Sujet(s)
Xeroderma pigmentosum , Humains , Xeroderma pigmentosum/génétique , Réparation de l'ADN/génétique , Dimères de pyrimidine/génétique , Dimères de pyrimidine/métabolisme , Altération de l'ADN/génétique , ADN/génétique , Rayons ultraviolets , Protéine-1 de complémentation croisée de la réparation des lésions induites par les rayons X/métabolisme
18.
BMJ Case Rep ; 16(10)2023 Oct 17.
Article de Anglais | MEDLINE | ID: mdl-37848274

RÉSUMÉ

Xeroderma pigmentosum-Cockayne syndrome complex (XP-CS) is exceedingly rare, with 43 cases described over the past five decades; 21 of these cases exhibited mutations in the ERCC5 endonuclease associated with xeroderma pigmentosum, group G.We report the first known phenotypic characterisation of the homozygous chromosome 13 ERCC5, Exon 11, c.2413G>A (p.Gly805Arg) missense mutation in a female toddler presenting with findings of both XP and CS.Her severe presentation also questions previous hypotheses that only truncating mutations and early missense mutations of XPG are capable of producing the dire findings of XP-CS.


Sujet(s)
Syndrome de Cockayne , Xeroderma pigmentosum , Humains , Femelle , Xeroderma pigmentosum/complications , Xeroderma pigmentosum/génétique , Mutation faux-sens , Syndrome de Cockayne/diagnostic , Syndrome de Cockayne/génétique , Syndrome de Cockayne/complications , Mutation
19.
BMC Med Genomics ; 16(1): 186, 2023 08 12.
Article de Anglais | MEDLINE | ID: mdl-37573316

RÉSUMÉ

BACKGROUND: Xeroderma pigmentosum group E (XP-E) is one of the least common forms of XP, a rare syndrome where patients are prone to develop skin cancer in exposed sunlight areas. XP-E patients are generally not diagnosed until they are adults due to the mild phenotype. CASE PRESENTATION: two XP-E siblings, female, 23 years, and male, 25 years, from a Brazilian consanguineous family carrying the novel missense pathogenic variant in DDB2 gene, NM_000107.3:c.1027G > C, associated with skin cancer early-onset and severe phenotype, as nodular melanoma in the cornea and in the ear. CONCLUSION: The assessment of genomic variant pathogenicity was a challenge since this family belongs to an underrepresented population in genomic databases. Given the scarcity of literature documenting XP-E cases and the challenges encountered in achieving an early diagnosis, this report emphasizes the imperative of sun protection measures in XP-E patients. Additionally, it highlights the detrimental impact of the COVID-19 pandemic on cancer diagnosis, leading to the manifestation of a severe phenotype in affected individuals.


Sujet(s)
COVID-19 , Mélanome , Tumeurs cutanées , Xeroderma pigmentosum , Mâle , Femelle , Humains , Xeroderma pigmentosum/génétique , Xeroderma pigmentosum/épidémiologie , Xeroderma pigmentosum/anatomopathologie , Brésil , Pandémies , Fratrie , COVID-19/épidémiologie , Mélanome/génétique , Tumeurs cutanées/génétique , Réparation de l'ADN , Protéines de liaison à l'ADN/génétique
20.
Mol Biol Rep ; 50(8): 6843-6850, 2023 Aug.
Article de Anglais | MEDLINE | ID: mdl-37392287

RÉSUMÉ

BACKGROUND: The effective maintenance of genome integrity and fidelity is vital for the normal function of our tissues and organs, and the prevention of diseases. DNA repair pathways maintain genome stability, and the adequacy of genes acting in these pathways is essential for disease suppression and direct treatment responses. Chronic kidney disease is characterized by high levels of genomic damage. In this study, we examined the expression levels of the xeroderma pigmentosum group D (XPD) gene, which plays a role in the nucleotide excision repair (NER) repair mechanism, and the expression levels of miR-145 and miR-770 genes, which play a role in the regulation of the expression of the XPD gene, in hemodialysis patients with (n = 42) and without malignancy (n = 9) in pre- and post-dialysis conditions. We also evaluated these values with the clinical findings of the patients. METHODS & RESULTS: Gene expression analysis was performed by real-time polymerase chain reaction (qRT-PCR). Compared to the individuals with normal kidney function (2.06 ± 0.32), the XPD gene expression was lower in the pre-dialysis condition both in hemodialysis patients without cancer (1.24 ± 0.18; p = 0.02) and in hemodialysis patients with cancer (0.82 ± 0.114; p = 0.001). On the other hand, we found that miR-145 and miR-770 expression levels were high in both groups. We also found that expression levels were affected by dialysis processes. A statistically significant positive correlation was found between miR-145 and mir770 expression levels in the pre-dialysis group of patients with (r=-0.988. p = 0.0001) and without (r=-0.934. p = 0.0001) malignancy. CONCLUSIONS: Studies on DNA damage repair in the kidney will help develop strategies to protect kidney function against kidney diseases.


Sujet(s)
Défaillance rénale chronique , microARN , Xeroderma pigmentosum , Humains , Xeroderma pigmentosum/génétique , Xeroderma pigmentosum/métabolisme , Protéine du groupe de complémentation D de Xeroderma pigmentosum/génétique , Protéine du groupe de complémentation D de Xeroderma pigmentosum/métabolisme , Réparation de l'ADN/génétique , Défaillance rénale chronique/génétique , Défaillance rénale chronique/thérapie , microARN/génétique , Prédisposition génétique à une maladie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...